Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure drug trial halted early

NCT ID NCT06142383

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called XXB750 in 136 people with heart failure. The goal was to see if it could improve heart function and symptoms. The trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
XXB750 (an experimental biologic given as an injection)
What this could lead to
If successful, XXB750 could offer a new treatment option for people with heart failure, potentially improving heart function and reducing symptoms.
What could go wrong
This was an early phase 2 trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

136 people

The number who actually took part.

Started

Dec 2023

Finished

Nov 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Current symptom(s) of HF NYHA class II-III and LVEF \< 50% * Elevated NT-proBNP levels at screening. * Receiving standard of care background HF therapy. Exclusion Criteria: * Current acute decompensated HF or hospitalization for HF within 3 months prior to screening. * Current symptomatic hypotension (for example dizziness/presyncope). * K+ \> 5.4 mmol/L at screening * eGFR \< 30 mL/min/1.73m2 at screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

Contacts and locations

Locations

  • American Clinical Trials

    Acworth, Georgia, 30101, United States

  • Anderson Medical Research

    Ft. Washington, Maryland, 20744, United States

  • Aultman Hospital

    Canton, Ohio, 44710, United States

  • Cardiology Partners Clinical Research Institute

    Wellington, Florida, 33449, United States

  • Dominion Medical Associates

    Richmond, Virginia, 23219, United States

  • Heart Center Research Llc

    Huntsville, Alabama, 35801, United States

  • Heart Clinic of Hammond

    Hammond, Louisiana, 70403, United States

  • Inpatient Research Clinical LLC

    Miami Lakes, Florida, 33014, United States

  • Nature Coast Clinical Research LLC

    Inverness, Florida, 34452, United States

  • NexGen Research

    Lima, Ohio, 45801, United States

  • Novartis Investigative Site

    Blagoevgrad, 270 0, Bulgaria

  • Novartis Investigative Site

    Gabrovo, 5300, Bulgaria

  • Novartis Investigative Site

    Kyustendil, 2500, Bulgaria

  • Novartis Investigative Site

    Pleven, 5800, Bulgaria

  • Novartis Investigative Site

    Plovdiv, 4002, Bulgaria

  • Novartis Investigative Site

    Sofia, 1233, Bulgaria

  • Novartis Investigative Site

    Sofia, 1510, Bulgaria

  • Novartis Investigative Site

    Varna, 9010, Bulgaria

  • Novartis Investigative Site

    Xian, Shanxi, 710061, China

  • Novartis Investigative Site

    Berlin, 13347, Germany

  • Novartis Investigative Site

    Cologne, 51065, Germany

  • Novartis Investigative Site

    Gladbeck, 45968, Germany

  • Novartis Investigative Site

    Kiel, 24105, Germany

  • Novartis Investigative Site

    Ludwigshafen, 67067, Germany

  • Novartis Investigative Site

    Papenburg, 26871, Germany

  • Novartis Investigative Site

    Schwäbisch Hall, 74523, Germany

  • Novartis Investigative Site

    Budapest, Pest County, 1134, Hungary

  • Novartis Investigative Site

    Balatonfüred, 8230, Hungary

  • Novartis Investigative Site

    Belagavi, Karnataka, 590010, India

  • Novartis Investigative Site

    Bikaner, Rajasthan, 334003, India

  • Novartis Investigative Site

    Brescia, BS, 25123, Italy

  • Novartis Investigative Site

    Messina, ME, 98125, Italy

  • Novartis Investigative Site

    Milan, MI, 20138, Italy

  • Novartis Investigative Site

    Pordenone, PN, 33170, Italy

  • Novartis Investigative Site

    Roma, RM, 00133, Italy

  • Novartis Investigative Site

    Roma, RM, 00168, Italy

  • Novartis Investigative Site

    Trieste, TS, 34149, Italy

  • Novartis Investigative Site

    Maebashi, Gunma, 371 8511, Japan

  • Novartis Investigative Site

    Kawasaki, Kanagawa, 216-8511, Japan

  • Novartis Investigative Site

    Sagamihara, Kanagawa, 252-0375, Japan

  • Novartis Investigative Site

    Matsumoto, Nagano, 390-8621, Japan

  • Novartis Investigative Site

    Lisbon, 1449-005, Portugal

  • Novartis Investigative Site

    Vila Nova de Gaia, 4434 502, Portugal

  • Novartis Investigative Site

    Bardejov, Slovakia, 085 01, Slovakia

  • Novartis Investigative Site

    Košice, Slovakia, 040 01, Slovakia

  • Novartis Investigative Site

    Martin, Slovakia, 036 01, Slovakia

  • Novartis Investigative Site

    Nitra, Slovakia, 949 11, Slovakia

  • Novartis Investigative Site

    Prešov, Slovakia, 080 01, Slovakia

  • Novartis Investigative Site

    Svidník, Slovakia, 089 01, Slovakia

  • Novartis Investigative Site

    Santiago Compostela, A Coruna, 15706, Spain

  • Novartis Investigative Site

    Huelva, Andalusia, 21005, Spain

  • Novartis Investigative Site

    Majadahonda, Madrid, 28222, Spain

  • Novartis Investigative Site

    Las Palmas GC, 35010, Spain

  • Novartis Investigative Site

    Madrid, 28041, Spain

  • Novartis Investigative Site

    Málaga, 29010, Spain

  • Novartis Investigative Site

    Valencia, 46010, Spain

  • Novartis Investigative Site

    Valencia, 46026, Spain

  • Novartis Investigative Site

    Taichung, 40447, Taiwan

  • Revival Research Institute

    Troy, Michigan, 48084, United States

  • SEC Clinical Research

    Dothan, Alabama, 36305, United States

  • Tennessee Center For Clinical Trials

    Tullahoma, Tennessee, 37388, United States

  • The Research Group

    Lexington, Kentucky, 40503, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.